August 19, 2025 — Leads & Copy — Agenus Inc. (Nasdaq: AGEN) will host a virtual Stakeholder Briefing on August 27, 2025, at 4:00 p.m. ET. The event will include presentations from senior management and industry thought leaders on developments that could shape the future of cancer treatment.
The agenda includes a strategic and financial overview, achievements tied to the Zydus partnership closing, patient needs fueling interest in colorectal cancer (CRC) studies, recent data from the botensilimab (BOT) and balstilimab (BAL) program, and an overview of the Phase 3 BATTMAN study in metastatic CRC, along with milestones and potential breakthroughs in immuno-oncology. The session will conclude with a live Q&A.
Speakers will include Garo H. Armen, PhD, Founder, Chairman, and CEO of Agenus; Jennifer Buell, PhD, CEO of MiNK Therapeutics/ Chair of Executive Committee of Agenus; Richard M. Goldberg, MD, Chief Development Officer of Agenus; Nicholas C. DeVito, MD, Assistant Professor of Medical Oncology at Duke University; Chris O’Callaghan, DVM, MSc, PhD, & Jonathan Loree, MD, MS, FRCPC (CCTG): Senior Investigators at Canadian Cancer Trials Group (CCTG).
Agenus is an immuno-oncology company targeting cancer with a pipeline of immunological agents and capabilities across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA.
Botensilimab is a multifunctional, human Fc enhanced CTLA-4 blocking antibody designed to boost both innate and adaptive anti-tumor immune responses, with clinical responses shown across nine metastatic, late-line cancers.
Balstilimab is a monoclonal immunoglobulin designed to block PD-1. It has demonstrated clinical activity and a favorable tolerability profile in several tumor types.
Contact:
Garo H. Armen, PhD, Founder, Chairman, CEO of Agenus
Richard M. Goldberg, MD, Chief Development Officer of Agenus
